Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications

Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications

To quantify the relationship of residual C-peptide secretion to glycemic outcomes and microvascular complications in type 1 diabetes. C-peptide was measured in an untimed blood sample in the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) cohort of 6,076 people with type 1 diabetes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes care 2021-02, Vol.44 (2), p.390-398
Hauptverfasser: Jeyam, Anita, Colhoun, Helen, McGurnaghan, Stuart, Blackbourn, Luke, McDonald, Timothy J, Palmer, Colin N A, McKnight, John A, Strachan, Mark W J, Patrick, Alan W, Chalmers, John, Lindsay, Robert S, Petrie, John R, Thekkepat, Sandeep, Collier, Andrew, MacRury, Sandra, McKeigue, Paul M
Format: Artikel
Sprache:eng
Schlagworte:
Blood glucose
Clinical trials
Complications
Diabetes
Diabetes mellitus
Diabetes mellitus (insulin dependent)
Diabetic ketoacidosis
Hypoglycemia
Insulin
Ketoacidosis
Microvasculature
Pancreas
Peptides
Recovery of function
Regression analysis
Regression models
Research design
Retinopathy
Secretion
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To quantify the relationship of residual C-peptide secretion to glycemic outcomes and microvascular complications in type 1 diabetes. C-peptide was measured in an untimed blood sample in the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) cohort of 6,076 people with type 1 diabetes monitored for an average of 5.2 years. In regression models adjusted for age at onset and duration, effect sizes for C-peptide ≥200 vs.
ISSN:0149-5992
1935-5548
DOI:10.2337/dc20-0567